Overall, we identified a significant difference in the frequency of mutations in the MAPK pathway (BRAF, NRAS, or KRAS mutation) between SMM and MM (24% vs. 44%, χ2 = 9.2, p = 0.002). This evidence concerns the gene NRAS and Miyoshi myopathy.